Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-11-26
2000-02-15
Stanton, Brian R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 6, 435 691, 4351723, 536 245, 935 33, 935 65, A61K 4800, C12N 1511, C12N 1509
Patent
active
060253398
ABSTRACT:
A method of reducing bronchoconstriction in a subject in need of such treatment is disclosed. The method comprises administering to the subject an antisense oligonucleotide molecule directed against the A.sub.1 or A.sub.3 adenosine receptor in an amount effective to reduce bronchoconstriction. The method is useful for treating patients afflicted with asthma. Pharmaceutical formulations are also disclosed.
REFERENCES:
patent: 5225326 (1993-07-01), Bresser et al.
patent: 5245022 (1993-09-01), Weis et al.
patent: 5320962 (1994-06-01), Stiles et al.
patent: 5585479 (1996-12-01), Hoke et al.
Stull et al. "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects," Pharmaceutical Research, vol. 12, No. 4: 46j5-483, 1995.
Miller et al. "Gene Transfer and Antisense Nucleic Acid Techniques," Parasitology Today, vol. 10, No. 3: 92-97, 1994.
Wu Pong, S. "Oligonucleotides: Opportunities for Drug Therapy and Research," Pharmaceutical Technology, vol. 18: 102-114, Oct. 1994.
Nyce, J.W., "Respirable Antisense Oligonucleotides as Novel Therapeutic Agents for Asthma and Other Pulmonary Diseases", Exp. Opin. Invest. Drugs, 6(9): 1-7, (1997).
Nyce, J.W. et al., "DNA Antisense Therapy for Asthma in an Animal Model", Nature, 385(20): 721-725, (1997).
Akhter, S. et al., "In Vivo Studies with Antisense Oligonucleotides", Trends in Pharmacol. Sciences, 18: 12-18, (1997).
Webb, A. et al., "BCL-2 Antisense Therapy in Patients with Non-Hodgkin Lymphoma", Lancet, 349(9059): 1137-41, (1997).
Yazaki, T. et al., "Treatment of Glioblastoma U-87 by Systemic Administration of an Antisense Protein Kinase C-Alpha Phosphorothioate Oligodeoxynucleotide", Molecular Pharmacol., 50(2): 236-242, (1996).
Farmer, S.G. et al., "Adenosine Receptor-mediated Contraction and Relaxation of Guinea-pig Isolated Tracheal Smooth Muscle: Effects of Adenosine Antagonists", Br. J. Pharmacol., 95: 371-378 (1988).
Marquardt, D.L. et al., "Aminophylline Exposure Alters Mouse Bone Marrow-derived Mast Cell Adenosine Responsiveness", J. Allergy Clin Immunol. 78: 462-469, (1986).
J. Milligan et al.; Current Concepts in Antisense Drug Design. J. Med. Chem. 36(14): 1923-1937 (1993).
S. Ali et al.; Adenosine-induced bronchoconstriction in an allergic rabbit model:antagonism by theophylline aerosol. Agents Actions 37:165-167 (1992).
S. Ali et al.; Modification of allergen-induced airway obstruction and bronchial hyperresponsiveness in the allergic rabbit by theophylline aerosol. Agents Actions 37:168-170 (1992).
S. Ali et al.; Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Adenosine A.sub.1 Receptor. J. Pharmacol. Exp. Therapeu. 268:1328-1334 (1994).
S. Ali et al.; Adenosine receptor-mediated bronchoconstriction and bronchial hyperresponsiveness in allergic rabbit model. Am. J. Physiol. 266:L271-277 (1994).
D.R. Sibley, et al; Transfected Mammalian Cell Lines Expressing the A1 Adenosine Receptor NTIS Field/Group Codes: 57F, 57B, 57Q 90D (Jun. 5, 1991).
Amzel Viviana
East Carolina University
Hauda Karen M.
Stanton Brian R.
LandOfFree
Composition, kit and method for treatment of disorders associate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition, kit and method for treatment of disorders associate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition, kit and method for treatment of disorders associate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1905995